Corcept Therapeutics shares slipped after hours after reporting weaker-than-expected Q4 profits and revenue. Despite net income falling, demand for its Cushing syndrome treatment surged with record prescriptions. The company guided for $900 million to $1 billion in 2026 revenue. Investors are now focused on a critical April FDA meeting regarding the relacorilant rejection.